| Index | Ligand Name | Structure | PDB code | ligand desolvation |
| 1 | cg5 | Crystal structure of human Casein Kinase I delta in complex with compound 31a | 6f1w | 91.35 |
| 2 | 15g | Crystal structure of ck1d with compound 13 | 4hgt | 90.15 |
| 3 | 0ck | crystal structure of ck1d with PF670462 from P21 crystal form | 3uzp | 89.77 |
| 4 | 0ck | crystal structure of ck1d with PF670462 from P1 crystal form | 3uyt | 89.56 |
| 5 | 1qn | CK1d in complex with 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE ligand | 4kb8 | 88.04 |
| 6 | 1qm | CK1d in complex with 9-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2,3,4,5-tetrahydropyrido[2,3-f][1,4]oxazepine inhibitor | 4kba | 87.8 |
| 7 | 37j | 2-Benzamido-N-(1H-benzo[d]imidazol-2-yl)thiazole-4- carboxamide derivatives as potent inhibitors of CK1d/e | 4twc | 85.49 |
| 8 | 386 | Difluoro-dioxolo-benzoimidazol-benzamides as potent inhibitors of CK1delta and epsilon with nanomolar inhibitory activity on cancer cell proliferation | 4tw9 | 84.97 |
| 9 | 9wg | Identification and Profiling of a Selective and Brain Penetrant Radioligand for In Vivo Target Occupancy Measurement of Casein Kinase 1 (CK1) Inhibitors | 5w4w | 84.13 |
| 10 | 16w | Crystal structure of ck1d in complex with pf4800567 | 4hnf | 83.37 |
| 11 | pfo | CK1d in complex with inhibitor | 4tn6 | 82.82 |
| 12 | 1qg | CK1d in complex with (3S)-3-{4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridin-2-yl}morpholine inhibitor | 4kbk | 82.68 |
| 13 | d5q | Crystal structure of human Casein Kinase I delta in complex with 4-(2,5-Dimethoxyphenyl)-N-(4-(5-(4-fluorphenyl)-2-(methylthio)-1H-imidazol-4-yl)-pyridin-2-yl)-1-methyl-1H-pyrrole-2-carboxamide | 5mqv | 78.74 |
| 14 | c9z | Crystal structure of human Casein Kinase I delta in complex with compound 31b | 6f26 | 65.1 |
| 15 | 9xk | Crystal structure of human Casein Kinase I delta in complex with IWP-2 | 5okt | 60.35 |